Expert Opin Biol Ther
Idecabtagene Vicleucel for Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Mancuso K, Barbato S, Talarico M, et al
In this review, the authors summarize the most recent updates related to the use of idcabtagene vicleucel from ongoing or upcoming clinical trials, and from real-world experiences.
Previous Article
- • 3-Year Follow-Up From the Randomized, Phase 3 TRANSFORM Study
- • Final Results of the Phase 2 PILOT Study in Relapsed/Refractory Large B-Cell Lymphoma
- • Case Series: Lisocabtagene Maraleucel for Richter’s Transformation
- • Real-World Analysis of Lisocabtagene Maraleucel for Relapsed/Refractory Large B-cell Lymphoma
- • Implementation of a Lisocabtagene Maraleucel Outpatient Monitoring Program
- • Lisocabtagene Maraleucel Versus Second-Line Chemotherapy Regimens in the Real World
- • Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
- • Idecabtagene Vicleucel in Patients With Relapsed/Refractory Multiple Myeloma
- • Outcomes of Older Adults and Frail Patients Treated With Idecabtagene Vicleucel
- • Idecabtagene Vicleucel for Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
- • KarMMa-3 Analyses: Idecabtagene Vicleucel in Triple Class-Exposed RRMM
- • Real-World Experience: Idecabtagene Vicleucel in Older Patients With Multiple Myeloma
